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Abstract
Background: The need for tetanus toxoid decennial booster doses has been questioned by some
experts. Several counter arguments have been presented, supporting the maintenance of decennial adult
booster doses with tetanus and diphtheria toxoids (adult formulation of the vaccine: Td). This study aimed
to evaluate the use of Td in Portuguese adult women under routine conditions. For that purpose we
selected a group of women 30+ years of age to which vaccination was recommended. We intended to
know if pre-vaccination antibody concentrations were associated with factors as age at first and last
vaccination, number of doses and time since last revaccination. We also intended to assess the serological
efficacy of Td booster.
Methods: Following the Portuguese guidelines 100 women were vaccinated with Td. Antitetanus toxin
IgG (ATT IgG) and antidiphtheria toxin IgG (ADT IgG) levels were measured (mIU/ml) in 100 pre-
vaccination and 91 post-vaccination sera. Detailed vaccination records were available from 88 participants.
Results: Twenty-two women (Group A) began vaccination with DPT/DT in their early childhood and
their pre-vaccination ATT IgG levels increased with the number of doses received (p = 0.022) and
decreased with time since last vaccination (p = 0.016). Among the 66 women who began vaccination in
adolescence and adulthood (Group B), with monovalent TT, ATT IgG levels decreased with age at first
dose (p < 0.001) and with time since last vaccination (p = 0.041). In Group A, antidiphtheria toxin IgG
kinetics was very similar to that observed for ATT IgG. Among women not vaccinated with diphtheria
toxoid, ADT IgG levels decreased with age. Serological response to both components of Td was good but
more pronounced for ATT IgG.
Conclusion: Our study suggests that, to protect against tetanus, there is no need to administer decennial
boosters to the Portuguese adults who have complied with the childhood/adolescent schedule (6 doses of
tetanus toxoid). The adult booster intervals could be wider, probably of 20 years. This also seems to apply
to protection against diphtheria, but issues on the herd immunity and on the circulation of toxigenic strains
need to be better understood.
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Background
Tetanus and diphtheria toxoids have been used in differ-
ent vaccine formulations, to immunise against tetanus
and diphtheria [1,2]. DPT and DT (diphtheria-tetanus-
pertussis and diphtheria-tetanus vaccines) have been used
in primary immunisation in early childhood [1,2].
The degree and duration of immunity against tetanus
increases with the number of doses of tetanus toxoid
given [3] and there is a continuous decline in antitetanus
toxin serum concentration after primary vaccination as
well as revaccination [4]. Three doses of tetanus toxoid are
necessary for primary immunisation, in early childhood
as later in life (adults) [3,4] and many countries have rec-
ommend the use of 3 doses of DPT in early childhood
[5,6]. Revaccination strategies and schedules vary widely
[7].
For diphtheria, it was more difficult to draw conclusions
about the effect of primary vaccination, because response
was influenced by naturally acquired immunity [4]. Stud-
ies in populations with little or no diphtheria have shown
that antibody kinetics after vaccination is similar to that
observed for tetanus vaccination [4].
For many years, several countries have recommended
decennial boosters to adults, using the monovalent teta-
nus vaccine (TT) [5,6].
Initial attempts to use booster doses of diphtheria toxoid
were associated with high rates of adverse reactions [2,8]
and vaccination programmes did not include adult boost-
ers [5]. To overcome that problem, a Td combination
(with a lower amount of diphtheria toxoid) was eventu-
ally developed for use in adults [9]. Meanwhile, diphthe-
ria epidemics occurred in the former Soviet Union states
[2,10,11]. Coupled with serological data showing low lev-
els of protection among adults in several West European
countries [2,11,12] that epidemic raised the concerns of
resurgence of diphtheria in those countries, leading to the
recommendation to replace TT by Td in the adult decen-
nial boosters [2,11].
The need for tetanus toxoid decennial booster doses has
been questioned by some experts [1,4,9,13-15]. The main
argument was that few cases of tetanus have been
observed among people who received the primary vacci-
nation series, regardless they had received booster doses
[1]. Further arguments against decennial boosters include
cost-effectiveness considerations [14] and the concerns
with post Td adverse reactions [9]. As an alternative it has
been proposed in the USA that, following a primary child-
hood series and teenage/young adult booster, no further
boosters should be given until 50 years of age, except as
part of procedures recommended in wound management
[1,9]. This lead to an interesting situation in the USA,
where the Advisory Committee on Immunization Prac-
tices has continued to recommend boosters every 10
years, but in the official guidelines [15] it is also men-
tioned the alternative proposed by the American College
of Physicians.
Central to this discussion have been the studies of
Simonsen, in Denmark [4,16]. He measured antitetanus
toxin IgG (ATT IgG) serum levels and used linear regres-
sion models to assess the duration of immunity after vac-
cination with primary series and after revaccination
[4,16]. Consequent to his observations, Simonsen pro-
posed to the Danish population a school age booster after
primary immunization, followed by routine boosters
every 20 years [1,16].
Several counter arguments have been presented, support-
ing the maintenance of decennial adult booster doses
with Td [1]. It was argued that the recommendations to
the Danish population could lead to significant propor-
tions of unprotected adults in other populations [1]. The
rationale for decennial tetanus toxoid boosters is to main-
tain serum ATT IgG well above protective levels for nearly
all members of the population [1]. Furthermore, severe
cases and deaths due to tetanus were observed among pre-
viously vaccinated people, and older adults may not have
as great or long lasting responses to a single booster as
younger individuals [1,17]. Post-vaccination antidiphthe-
ria toxin IgG (ADT IgG) levels decline more rapidly than
ATT IgG levels, which has been considered "the final con-
sideration" to support decennial boosters with Td [1].
In Portugal, although vaccination had been available for
years, a comprehensive, nation-wide vaccination program
(NVP) only began in 1966 [18]. Primary vaccination with
3 doses of DPT was recommended in the first year of life
[18,19]. Booster doses of DPT were recommended at age
18–24 months and 5–6 years [19,20]. Booster doses with
TT were recommended at 11–13 years of age and every 10
years afterwards [20]. DT vaccine was recommended as an
alternative to DPT for those reporting serious adverse reac-
tions after DPT or for primary vaccination of children
aged 7–9, while TT should be given to adults to complete
the primary series [19]. For adults without vaccination
records or who had never received tetanus toxoid, primary
vaccination was recommended, with 3 doses, followed by
a booster 6–12 months after the third dose; for women in
childbearing age, an additional booster (5th dose) was rec-
ommended 1–5 years after the third dose; after that,
decennial boosters were recommended for both sexes
[20].
Since 2001, Td has replaced the TT in adolescent and adult
decennial boosters, and in primary vaccination of adultsBMC Public Health 2007, 7:109 http://www.biomedcentral.com/1471-2458/7/109
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who need it [20]. This change was influenced by the evi-
dence published in the international literature and by a
study among Portuguese recruits [12].
In January 2006, DPwT (with whole cell pertussis compo-
nent) was replaced by a DPaT (acellular pertussis); the
number of doses and recommended schedule was kept;
Td has also replaced DT, for primary immunisation for
those 7+ years [21].
We have only studied women because men are vaccinated
when they are conscripts [12] and those booster doses are
seldom recorded in vaccination records.
This study aimed to evaluate the use of Td in Portuguese
adult women under routine conditions. For that purpose
we selected a group of women 30+ years of age to which
Td vaccination was recommended by the NVP guidelines.
We intended to know if pre-vaccination antibody concen-
trations were associated with factors as age at first and last
vaccination, number of doses and time since last revacci-
nation. We also intended to assess the serological efficacy
of Td booster.
Methods
Study design and enrolment
From the computerised records of two General Practition-
ers, we identified 324 women 30+ years of age, who had
received tetanus vaccine more than 10 years before or who
had no vaccinations recorded. The computerised database
included information on vaccination, transcribed from
the written individual vaccination records kept in the vac-
cination room of the health centre (HC) of Condeixa-a-
Nova, Coimbra, Portugal. All operational and ethical
aspects of the study were authorized by the Portuguese
National Health Service coordinating board, at district
level (Sub-Região de Saúde de Coimbra), after a detailed
written study protocol had been submitted.
Those women were contacted by telephone and asked to
attend the HC to be vaccinated with Td. They were asked
to bring their individual vaccination booklet. If a tele-
phone number was not available or they did not answer
the calls, they were sent a post card. When attending the
vaccination room, their vaccination booklet was checked
against the written record in the HC. Participants signed
an informed consent, had a blood sample collected by
venupuncture and were vaccinated: the 100 participants
were given an intradeltoid injection of 0.5 ml of ANA-
TOXAL Di Te Berna Adultos® (batch 8500005) containing
purified tetanus-toxoid (corresponding to a potency ≥20
IU) and diphtheria-toxoid (potency ≥2 IU), adsorbed to
aluminum hydroxide; in the remaining text we just men-
tion that women were vaccinated with "Td".
The first 109 women attending the vaccination room
agreed to participate but nine were excluded because they
presented updated vaccination records showing they did
not need to be revaccinated. Women without individual
vaccination booklets were stimulated to bring them to the
HC, still after being vaccinated with Td, should they find
those records. One hundred and ten women never
attended the HC to be vaccinated. After the intended
number of 100 vaccinated participants was recruited,
women attending the vaccination room just received Td as
recommended [20] and we did not collect data about
them.
Laboratory procedures
Blood samples were allowed to clot at room temperature
and then serum was separated, frozen, and transported in
appropriate containers to the lab where they were kept at
-70°C till testing. All samples were studied at the Serology
Laboratory of the National Institute of Health, in Porto,
Portugal. Antitetanus toxin IgG (ATT IgG) was measured
using a commercial enzyme immunoassay (EIA) (Tetanus
ELISA IgG Testkit®, Genzyme Virotech GmbH). Using a cali-
bration curve, optical density (OD) measurements were
automatically converted into mIU/ml. Each serum was
tested twice and the result was the arithmetic mean of the
two measurements (in mIU/ml). Following the recom-
mendations of the EIA manufacturer, sera were also given
a qualitative classification. For Antidiphtheria toxin IgG
(ADT IgG) the lab procedures were identical but using the
commercial EIA (Diphtheria Tetanus ELISA IgG Testkit®,
Genzyme Virotech GmbH).
ATT IgG levels ≥160 mIU/ml were considered protective,
because such threshold has been recommended [3] and
used [22] when EIA technique is performed; according to
that threshold, women were classified as "immune" or
"susceptible" to tetanus.
ADT IgG levels ≥100 mIU/ml were considered protective,
because such threshold has been recommended [23] and
used [24] when EIA technique is performed; according to
that threshold, women were classified as "immune" or
"susceptible" to diphtheria. Additionally, we considered
those with levels ≥1000 mIU/ml has having "long-term
protection" [2,25].
Data analysis and statistical methods
Data were entered twice by independent operators and
validated using Epi Info 6.04 d [26], and analysed using
Stata [27] software.
The total number of tetanus toxoid and diphtheria toxoid
doses received by each woman was used as an independ-
ent variable in different analysis. Moreover we considered
the variable "primary vaccination" or "primary series"BMC Public Health 2007, 7:109 http://www.biomedcentral.com/1471-2458/7/109
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(yes/no) for both tetanus and diphtheria vaccination
depending on having received 3+ doses of the correspond-
ing toxoid in their lifetime.
Antibody concentration distributions in pre and post-vac-
cination sera, and the corresponding concentration differ-
ences were log-transformed to obtain a more closely
normal distribution to be used in the statistical analysis.
Thus, geometric mean concentration (GMC) values
reported in the text in mIU/ml correspond to anti-logs.
Few pre and post-vaccination sera had no detectable levels
of ADT IgG (concentration = 0 mIU/ml); to enable the
log-transformation, their inclusion in the regression mod-
els and the graphic display, we allocated those sera the
fake concentration value of 1 mIU/ml of ADT IgG. Simple
linear and multiple regression models [28] were used to
assess associations between antibody concentration levels
and differences between post and pre-vaccination levels,
as dependent variables, and number of vaccine doses,
time since last vaccination and age at first (and at last) vac-
cination, as independent variables. Analysis of variance
(Anova) was used to compare GMC between groups. Qui-
squared (χ2) test was used to compare proportions
between groups.
Results
Participant's mean age was 57.8 years (range 29.8–97.5
years, S.D. = 17.9). We do not have data on the reproduc-
tive life of women. Socioeconomic or clinical data were
not known. Initial blood sample collection (n = 100) and
vaccination, took place between May 15 and July 3, 2003.
Post-vaccination blood samples were collected from 91
women, in the HC, 46 to 96 days after vaccination (mean
= 64 and S.D. = 11 days).
Vaccination status
Td vaccine was given to the 100 participants, as recom-
mended by the Portuguese guidelines [20]: eighty-one
participants had received the last dose of tetanus-toxoid
more than 10 years before; initially, vaccination history
was unknown for 19 women. Some weeks latter, 7 of
these women presented written vaccination records show-
ing that they had received tetanus toxoid less than 10
years before; 5 of those had received less than 4 doses in
their life. After this update, we ended up with 12 women
without known vaccination history and 88 participants
for whom we knew types and numbers of vaccines
received at which exact dates. Among those without
known vaccination history, one was 66 and the others 77+
years of age.
The analysis of the vaccination history revealed two clear
patterns: some women were vaccinated in early childhood
with DPT (or DT) while others only began vaccination
later in life (with TT).
Twenty two women (Group A; n = 22) had begun their
vaccination against tetanus in childhood, receiving either
DPT before the age of 7 (n = 20) or DT, between 7–9 years
of age (n = 2); women in Group B (n = 66) began their
vaccination with TT after 10 years of age but only 4 were
vaccinated before their 20th birthday. Table 1 shows the
distribution of the two groups by age (and years of birth)
and vaccination history. Women in Group A were less
than 50 years of age and they were born between 1956
and 1973 while women in Group B were significantly
older (Table 1) and were born between 1913 and 1971. In
Group B, 85% of women were 10+ years of age when the
NVP began while in the younger Group A, none of the 9
women born before 1966 was 10 by the time the NVP
began (in 1966). Nevertheless, in 7 women of Group A,
the first dose of tetanus and diphtheria toxin was given
before 1966, while that was only recorded in one women
from Group B. Only 59.1% (39/66) of women in Group
B completed primary vaccination (3+ doses). All women
in Group A completed primary vaccination against teta-
nus and diphtheria. All 20 women who had begun vacci-
nation with DPT completed the primary series with the
same vaccine, 11 in the first year of life and 9 before 7
years of age. The 2 women, who began vaccination with
DT, completed the primary series when they were 11 and
18 years of age. By contrast, Group B began vaccination in
a much older age (Table 1), and among the 39 women
who completed primary vaccination against tetanus, 37
did it after their 30th birthday. Women who began vacci-
nation with DPT/DT received more lifetime doses of teta-
nus toxoid (Table 1); 2 of those had received up to 9
doses.
Only women from group A were vaccinated with diphthe-
ria toxoid. They received from 2 to 7 doses, and 21 out of
22 received at least the primary series (3 doses). The last
dose of diphtheria toxoid had been administered 20.0 to
38.7 years before.
Levels of antitetanus toxin IgG (ATT IgG) before 
vaccination
Geometric mean concentration (GMC) of antitetanus
toxin IgG (ATT IgG) in pre-vaccination sera (n = 100) was
832 mIU/ml, ranging from 40 to 15760 mIU/ml. Overall,
the proportion immune (≥160 mIU/ml) was 84% and
most susceptible women were 70+ years of age (Table 2).
GMC in groups A and B were respectively 1291 and 825
mIU/ml but the difference was not statistically significant
(p = 0.18).
In Group A (those who began vaccination with DPT/DT),
on univariate analysis, ATT IgG levels decreased with time
elapsed since last dose (log transformed variable) (Fig. 1;
p = 0.001). All women revaccinated in the last 20 years
had ATT IgG above the protective threshold and the 2 sus-BMC Public Health 2007, 7:109 http://www.biomedcentral.com/1471-2458/7/109
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ceptible women had been vaccinated more than 32 years
before (Fig. 1). ATT IgG levels increased with the number
of doses of tetanus toxoid ever received (Fig. 2; p = 0.002).
Only 2 women who had received 4–5 doses had ATT IgG
below the threshold of 160 mIU/ml (the above men-
tioned who had received the last tetanus toxoid injection
more than 32 years before). On univariate analysis neither
present age nor age at first vaccination were associated
with ATT IgG levels; age at last vaccination was significant
on univariate analysis but was dropped from the final
model because it was confounded by the effect of years
from last tetanus toxoid. The final model explained 56%
of variability of ATT IgG levels and included the total
number of tetanus toxoid doses and time since vaccina-
tion (Table 3).
In Group B (those who began vaccination with TT), on
univariate analysis, ATT IgG levels decreased with time
elapsed since last dose (log transformed variable) (Fig. 3;
p = 0.007). The levels of ATT IgG were not dependent (p
= 0.376) on the number of doses of tetanus toxoid
received, but all susceptible women (n = 9) had received
less than 4 doses of tetanus toxoid; on the other hand, 8
out of the 9 women who had received 4+ doses of tetanus
toxoid (Table 1) had received the last boost more than 10
years before. Furthermore, the decrease of ATT IgG levels
Table 1: Distribution of women who began vaccination with DPT/DT or TT, by age and vaccination history
Variable Value Group A: Began vaccination with DPT/DT (n = 22) Group B: Began vaccination with TT (n = 66) p value
Years of birth -
1910 – 1944 0 30
1945 – 1954 0 24
1955 – 1964 8 9
1965 – 1974 14 3
Age group (in years) <0.0001
30 – 39 14 3
40 – 49 8 13
50 – 59 0 25
60 – 69 0 12
70 – 99 0 13
N.° doses of tetanus toxoid <0.0001
10 1 5
20 1 2
30 3 1
42 2
53 6
6–9 17 0
Age at first dose <0.0001
Mean 2.2 41.2
S.D. 2.6 15.7
Min/Max 0.3/7.9 11.1/77.0
Time since last dose (years) 0.86
Mean 15.8 14.4
S.D. 7.3 6.0
Min/Max 5.0/34.4 1.6/33.0
Table 2: Numbers of immune and susceptible women to diphtheria and tetanus, by age group
Target disease Age group in years
Immunity (ATT IgG concentration) 30 – 39 40 – 49 50 – 59 60 – 69 70 – 98 Total
Tetanus
Immune (≥160 mIU/ml) 16 20 22 12 14 84
Susceptible (<160 mIU/ml) 1 1 3 1 10 16
Diphtheria
Immune (≥100 mIU/ml) 12 7 16 11 20 66
Susceptible (<100 mIU/ml) 5 14 9 2 4 34
T o t a l 1 72 12 51 32 4 * 1 0 0
* 100 pre-vaccination seraBMC Public Health 2007, 7:109 http://www.biomedcentral.com/1471-2458/7/109
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with time since last dose was only significant for those
who had received 3+ doses. ATT IgG levels were inversely
associated with the age at first vaccination (p < 0.001); all
9 women susceptible to tetanus had received the first dose
of tetanus toxoid after the age of 33 years (Fig. 4). On uni-
variate analysis, present age and age at last dose were also
significantly associated with ATT IgG levels (Table 3) but
they were dropped from the final model because of the
confounding effect of age at first vaccination. The final
model explained 32% of variability of ATT IgG levels and
included age at first vaccination with tetanus toxoid and
time since the last dose (Table 3).
Pre-vaccination GMC was lower (p = 0.046) among the 12
women without know vaccination history and the pro-
portion of susceptible was higher in this group (p = 0.02).
The 5 susceptible women were older than 85 years.
Among those 12 women, ATT IgG concentration
decreased with age (p = 0.032).
Levels of antitetanus toxin IgG (ATT IgG) after vaccination
GMC of ATT IgG among the 91 post-vaccination sera was
11204 mIU/ml, ranging from 320 to 52000 IU/ml. All
became immune against tetanus (≥160 mIU/ml; Fig. 5).
In only 3 pairs of sera, concentration of ATT IgG was lower
among post-vaccination sera; the 3 pre-vaccination levels
were extremely high (approximately 1000, 5000 and
150000 mIU/ml). Among the remaining 88 pairs, ATT
IgG levels were on average (geometric mean) 9681 mIU/
ml higher among post-vaccination sera (compared with
pre-vaccination levels), ranging from 200 to 49980 mIU/
ml. Post-vaccination ATT IgG levels were highly correlated
(p < 0.001) with pre-vaccination levels; when added to the
model, age (p = 0.64), time since last dose (p = 0.14)
Antitetanus toxin IgG (ATT IgG) levels in pre-vaccination  sera, by number of doses of tetanus-toxoid received in  women who began vaccination with DTP/PT (Group A) Figure 2
Antitetanus toxin IgG (ATT IgG) levels in pre-vaccination 
sera, by number of doses of tetanus-toxoid received in 
women who began vaccination with DTP/PT (Group A). 
Regression line (stippled) and threshold level of 160 mIU/ml.
n = 22
p = 0.002
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Table 3: Regression models assessing the association between independent variables and antitetanus toxin levels* in pre-vaccination 
sera of Group A and Group B women – p values
Independent variable Group Aa (n = 22) Group Bb (n = 66)
Univariate analysis Final model Univariate analysis Final model
Age in years 0.506 - <0.001 -
Age at first tetanus toxoid 0.132 - <0.001 <0.001
N.° doses of tetanus toxoid 0.002 0.022 0.376 -
Years since last tetanus toxoidc 0.001 0.016 0.007 0.041
Age at last tetanus toxoid 0.007 - 0.002 -
R2 -0 . 5 6-0 . 3 2
* Log transformation of values in mIU/ml
a: Group A = women who began vaccination with DPT/DT
b: Group B = women who began vaccination with TT
c: This variable was log transformed to be used in the models
Antitetanus toxin IgG (ATT IgG) levels in pre-vaccination  sera, by time since last dose of tetanus-toxoid in women who  began vaccination with DTP/PT (Group A) Figure 1
Antitetanus toxin IgG (ATT IgG) levels in pre-vaccination 
sera, by time since last dose of tetanus-toxoid in women who 
began vaccination with DTP/PT (Group A). Regression line 
(stippled) and threshold level of 160 mIU/ml.
n = 22
p = 0.001
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number of previous doses (p = 0.60) and belonging to
groups A or B, were not significantly associated with post-
vaccination levels.
Following the interpretation proposed by the EIA manu-
facturer (Table 4), none of the participants needed "basic
immunization" and only 37% required "booster vaccina-
tion". Following vaccination with Td, most women got
"extremely high protection" against tetanus but 2 women
still fell in the category "sufficient protection but booster
recommended": one of them was 89.7 years old and had
no vaccination records; the other was 55.6 years old and
had received 3 lifetime doses of tetanus toxoid, with the
last one 13.7 years before; this was the only women with
lower post-vaccination antibody levels (compared with
pre-vaccination levels) both for ATT IgG and ADT IgG.
Levels of antidiphtheria toxin IgG (ADT IgG) before 
vaccination
In 7 pre-vaccination sera ADT IgG was not measurable
(concentration = 0 mIU/ml). Among the remaining 93
sera GMC was 184 mIU/ml, ranging from 10 to 6030.
Most women (66%) were immune to diphtheria (ADT
IgG ≥100 mIU/ml) though only 6% had long-term protec-
tion (ADT IgG ≥1000 mIU/ml) (Table 5 and Fig. 6). The
distribution of immunes by age group was clearly differ-
ent for diphtheria or for tetanus (Table 2). The proportion
of women immune to diphtheria varied with age group (p
= 0.003; Table 2) with the lower proportion of immunes
in the 40–49 years group.
Among the 22 women who had received diphtheria tox-
oid (Group A), on univariate analysis, ADT IgG levels
increased with the number of doses of diphtheria toxoid
received (Fig. 7; p = 0.013); all women who had received
6+ doses were immune. On univariate analysis ADT IgG
levels were also associated with time since last dose (Fig.
8; p = 0.028) (in the case of diphtheria antibodies there
was no need for log transformation of this variable); all
susceptible women had received diphtheria toxoid more
than 25 years before. It was not possible to assess the rel-
ative weight of these two independent variables because
they were highly correlated with each other: women
receiving fewer doses were the ones that had received the
last dose longer ago. Present age was not associated with
ADT IgG levels.
Antitetanus toxin IgG (ATT IgG) levels before and after vac- cination Figure 5
Antitetanus toxin IgG (ATT IgG) levels before and after vac-
cination. Box plot. Threshold immunity level of 160 mIU/ml.
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Antitetanus toxin IgG (ATT IgG) levels in pre-vaccination  sera, by time since last dose of tetanus-toxoid in women who  began vaccination with TT (Group B) Figure 3
Antitetanus toxin IgG (ATT IgG) levels in pre-vaccination 
sera, by time since last dose of tetanus-toxoid in women who 
began vaccination with TT (Group B). Regression line (stip-
pled) and threshold level of 160 mIU/ml.
n = 66
p = 0.007
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Antitetanus toxin IgG (ATT IgG) levels in pre-vaccination  sera, by age at first dose of tetanus-toxoid received in  women who began vaccination with TT (Group B) Figure 4
Antitetanus toxin IgG (ATT IgG) levels in pre-vaccination 
sera, by age at first dose of tetanus-toxoid received in 
women who began vaccination with TT (Group B). Regres-
sion line (stippled) and threshold level of 160 mIU/ml.
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Among the 78 women who had never been vaccinated
with diphtheria toxoid or which vaccination status was
unknown, ADT IgG levels increased with age (p = 0.015).
Most of these women (96%) were 40+ years old.
Levels of antidiphtheria toxin IgG (ADT IgG) after 
vaccination
In 4 post-vaccination sera ADT IgG was not measurable
(concentration = 0 mIU/ml). Among the remaining 87
sera GMC was 2989 mIU/ml, ranging from 40 to 61760.
Most women (85/91 = 93.4%) were immune to diphthe-
ria (ADT IgG ≥100 mIU/ml) though only 74.7% (68/91)
had long-term protection (ADT IgG ≥1000 mIU/ml)
(Table 5 and Fig. 6). In 7 pairs of sera, concentration of
ATT IgG was the same or lower among post-vaccination
sera. Among the remaining 84 pairs, ADT IgG levels were
on average (geometric mean) 2983 mIU/ml higher
among post-vaccination sera (compared with pre-vaccina-
tion levels), ranging from 20 to 61570 mIU/ml. Post-vac-
cination ADT IgG levels were highly correlated (p < 0.001)
with pre-vaccination levels; when added to the model, age
was not significantly (p = 0.24) associated with post-vac-
cination levels.
Following the interpretation of the ELISA manufacturer
(Table 5), the 6 women with levels below 100 mIU/ml
after vaccination with Td, should receive "basic immuni-
zation immediately". All had just received one dose of
diphtheria toxoid in their lives.
Discussion
Vaccination history was highly dependent upon age,
which had already been found in countries with old
national vaccination programmes [4]. Groups named A
and B correspond to two generations of Portuguese citi-
zens. One group is younger and was "covered" in their
childhood by the existence of the NVP, while in the other
group (B) most women were more than 10 years when the
programme began. Though the differences in antibody
concentrations (for both pre and post-vaccination ATT
IgG and ADT IgG), between these two groups, were not
statistically significant, the factors that affected the ATT
IgG levels in pre-vaccination sera were different.
For those who began vaccination in childhood with DPT/
DT (Group A), the total number of doses and time since
last vaccination were determinant factors; all had received
a complete primary series (3 doses) and at least one
booster and no susceptibles were observed before 20 years
had elapsed from the last dose. Our findings are consist-
ent with those from Simonsen [4].
Among Group B most women began vaccination in adult-
hood, with TT, and ATT IgG decreased with time since vac-
cination and age at first dose, which partially agrees with
the mentioned Danish study [4]. In this group, several
women who had received their last dose more than 10
years before were susceptible and all women who had
begun vaccination before 30 years of age were immune.
The difference between Groups A and B in what concerns
the effect of time elapsed from the last dose, maybe due to
similar kinetics but longer duration of immunity among
Table 5: Interpretation of IgG antidiphtheria toxin values observed in 100 pre-vaccination and 91 post-vaccination sera, as proposed by 
the EIA manufacturer.
Concentration mIU/ml Vaccination Recommendation Before vaccination After vaccination
< 100 Basic immunisation immediately 34 6
[100 – 1000[ Booster vaccination immediately 60 17
[1000 – 1400[ Booster vaccination after 5 years 3 6
[1400 – 2000[ Booster vaccination after 7 years 1 5
≥ 2000 Booster vaccination after 10 years 2 57
Table 4: Interpretation of IgG antitetanus toxin values observed in 100 pre-vaccination and 91 post-vaccination sera, as proposed by 
the EIA manufacturer.
Concentration mIU/ml Vaccination protection Vaccination recommendation Before vaccination After vaccination
<= 30 No Basic immunization 0 0
]30 – 100] Not surely guaranteed Booster vaccination 8 0
]100 – 500] Existent Booster vaccination 29 2
]500 – 1000] Sufficient Control in 2 years 13 4
]1000 – 5000] Long term Control in 5–10 years 41 6
> 5000 Extremely high Control in 10 years 9 79BMC Public Health 2007, 7:109 http://www.biomedcentral.com/1471-2458/7/109
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those who receive boosters, relative to those who only
received the primary series (or less than that), already
observed by other authors [17]. We were surprised to find
no association with the number doses received within this
group, but that may be explained by the fact that most
women had not even completed the 3 doses plus 2 boost-
ers, recommended by the Portuguese NVP guidelines [20].
Furthermore, the decline in protective antibody levels
with time since vaccination was only significant among
those who had received 3+ doses, which again is in favour
of previous findings of insufficient protective effect of less
than 3 doses [1,17].
The distribution of protective antibody levels against
diphtheria also seems to show the existence of two differ-
ent population groups. Among women vaccinated in their
childhood (Group A), most were younger less than 40
years of age (14/22); variation in ADT IgG pre-vaccination
levels was associated with the number of doses and time
elapsed from the last dose, showing antibody kinetics
similar to that of ATT IgG, which had already been men-
tioned in the literature [4]. Nevertheless it was surprising
that only those vaccinated more than 30 years before were
susceptible. Like it has been hypothesized to explain sim-
ilar observations in Canada [4,13], naturally acquired
immunity may have contributed to maintain immunity
after vaccination, in some of the vaccinated women we
have studied. In the other group (Group B plus the 12
women without vaccination history) most women were
40+ years old (75/78) and ADT IgG levels increased with
age, consistent with the findings from the Portuguese
national serological survey (NSS) performed in 2001/
2002 [24]. These women belong to a generation who lived
in a time when diphtheria incidence was high in Portugal
and they may have been naturally immunised.
Response to vaccination (or revaccination), measured as
concentration in post-vaccination sera or as difference in
concentration between post and pre-vaccination sera,
depended on the pre-vaccination concentration levels,
both for tetanus and diphtheria, which is again in agree-
ment with previous published findings [4]. We did not
find significant influence of present age or age at first vac-
cination on the post-vaccination antibody response,
which is not in agreement with previous findings [17]. We
cannot find a reason for that negative finding besides the
wide variation of pre-vaccination levels, which in its turn
Antidiphtheria toxin IgG (ADT IgG) levels, by time since last  dose of diphtheria-toxoid, in pre-vaccination sera of women  who had been vaccinated with diphtheria-toxoid (Group A) Figure 8
Antidiphtheria toxin IgG (ADT IgG) levels, by time since last 
dose of diphtheria-toxoid, in pre-vaccination sera of women 
who had been vaccinated with diphtheria-toxoid (Group A). 
Regression line (stippled) and threshold level of 100 mIU/ml.
n = 22
p = 0.028
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Antidiphtheria toxin IgG (ADT IgG) levels before and after 
vaccination. Box plot. Thresholds of 100 and 1000 mIU/ml.
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could be due to factors not assessed in this study. Never-
theless our study confirms that, even in old people, safe
protective ATT IgG levels can be attained by revaccination
[1,17,29].
The post-vaccination ADT IgG levels lower in what con-
cerns protection, relative to tetanus, might be due to the
lower pre-vaccination levels of ADT IgG. On the other
hand, for almost all women vaccination with Td was a
booster for tetanus protection, while it was the first dose
of diphtheria toxoid ever received; even for those few
women in which diphtheria toxoid was a booster, longer
periods of time had elapsed from last vaccination.
Conclusion
Added to previous evidence published in the literature
elsewhere, our study suggests that, to protect against teta-
nus, there is no need to administer decennial boosters to
the Portuguese adults who have complied with the aggres-
sive childhood/adolescent schedule, which includes 6
doses of tetanus toxoid. The adult booster intervals could
be wider, probably of 20 years. This also seems to apply to
protection against diphtheria, but issues on the herd
immunity effect and on the circulation of toxigenic strains
need to be better understood.
On the other hand, our study shows that many Portu-
guese adult women born before the beginning of the NVP
are not adequately vaccinated against tetanus. That is par-
ticularly evident among women 70+ years of age. The
analysis of the few sporadic cases of tetanus, especially
among elderly women, reported in Portugal in the begin-
ning of this century, had shown that missed oportunities
to vaccinate are a problem [30]. In this generation, though
the duration of immunity following the primary series
also seems to be longer than ten years, the priority is com-
pleting the primary series and first boosters as recom-
mended.
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